KM
HTGM

Kalos Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Kalos Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-405
Closed -$24K – 266
2020
Q3 		$24K Hold
405
– – 0.01% 229
2020
Q2 		$52K Hold
405
– – 0.02% 210
2020
Q1 		$24K Buy
405
+33
+9% +$3.23K 0.01% 201
2019
Q4 		$48K Hold
372
– – 0.02% 199
2019
Q3 		$46K Hold
372
– – 0.02% 193
2019
Q2 		$111K Buy
372
+18
+5% +$7.51K 0.05% 182
2019
Q1 		$159K Sell
354
-59
-14% -$25.8K 0.1% 141
2018
Q4 		$179K Buy
413
+25
+6% +$15.5K 0.09% 166
2018
Q3 		$308K Buy
388
+177
+84% +$117K 0.17% 117
2018
Q2 		$137K Hold
211
– – 0.06% 187
2018
Q1 		$137K Buy
+211
New +$158K 0.08% 112

Other funds holding HTGM

CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $46.5B AUM 20.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return